OABI (OmniAb) ROE % Adjusted to Book Value: -13.38% (As of Mar. 2026)


OABI OmniAb Inc OABI
71 GF Score
Price $2.42
GF Value $2.27
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is OmniAb ROE % Adjusted to Book Value?

OmniAb OABI +1.47% 71 ROE % Adjusted to Book Value is -13.38% as of Mar. 2026. GuruFocus rates OABI with a GF Score™ of 71/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 4 warning signs investors should review.

OmniAb's ROE % for the quarter that ended in Mar. 2026 was -11.64%. OmniAb's PB Ratio for the quarter that ended in Mar. 2026 was 0.87. OmniAb's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -13.38%.

OmniAb ROE % Adjusted to Book Value Related Terms

OmniAb ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for OmniAb's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OmniAb ROE % Adjusted to Book Value Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 -6.41 -6.74 -13.73 -23.36

OmniAb Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.25 -29.27 -29.52 -20.83 -13.38

OABI vs VNDA, AVIR, UPB: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, OmniAb's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where OmniAb's ROE % Adjusted to Book Value falls into.


OABI
71GF Score
OmniAb Inc OABI
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OmniAb ROE % Adjusted to Book Value Calculation

OmniAb's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-23.36% / 1.00
=-23.36%

OmniAb's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-11.64% / 0.87
=-13.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -13.38% mean?
OmniAb (OABI) has a ROE % Adjusted to Book Value of -13.38% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OmniAb and its competitors.
Is OmniAb's ROE % Adjusted to Book Value too high?
OmniAb's current ROE % Adjusted to Book Value is -13.38%. Overall, OmniAb has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's ROE % Adjusted to Book Value compare to VNDA and AVIR?
OmniAb's ROE % Adjusted to Book Value of -13.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OmniAb and its competitors. OmniAb's current ROE % Adjusted to Book Value is -13.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.42 — trading 6.6% above its estimated fair value. The current ROE % Adjusted to Book Value is -13.38%. OmniAb's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For OmniAb (OABI), the current ROE % Adjusted to Book Value is -13.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OmniAb (OABI) Overvalued in 2026?

Based on GuruFocus' analysis, OmniAb stock appears to be overvalued. The current stock price of $2.42 is trading 6.6% above its estimated GF Value™ of $2.27. GuruFocus considers OmniAb to be Fairly Valued.

Key valuation signals for OABI:

  • ROE % Adjusted to Book Value: -13.38%
  • GF Value™: $2.27 vs. price of $2.42 (6.6% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OmniAb Business Description

Address 5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
71GF Score

Get the complete analysis for OABI

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.42
Price
$2.27
GF Value